News
Investing.com -- Precision BioSciences (NASDAQ: DTIL) has received FDA Orphan Drug Designations for its nuclease treatments targeting Duchenne muscular dystrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback